Genflow Biosciences PLC Announces Launch of AI-Powered Partnership
Genflow Biosciences (GENFF) has entered into a strategic partnership with Heureka Labs, signing a Master Services Agreement on April 11, 2025. The collaboration provides Genflow access to Heureka's proprietary AI platform, specialized in analyzing genomic data and gene expression profiles.
The partnership will support Genflow's lead candidate GF-1002, a SIRT6-based gene therapy in preclinical evaluation, and may extend to other programs including those targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). Under the agreement, Genflow retains all IP rights.
Heureka Labs, a Duke University technology spin-off, offers an AI platform currently used by leading pharmaceutical companies to accelerate drug discovery through hypothesis generation and pattern recognition in biological data.
Genflow Biosciences (GENFF) ha stipulato una partnership strategica con Heureka Labs, firmando un Master Services Agreement l'11 aprile 2025. La collaborazione consente a Genflow di accedere alla piattaforma AI proprietaria di Heureka, specializzata nell'analisi dei dati genomici e dei profili di espressione genica.
La partnership supporterà il candidato principale di Genflow, GF-1002, una terapia genica basata su SIRT6 attualmente in fase di valutazione preclinica, e potrebbe estendersi ad altri programmi, inclusi quelli mirati alla Steatoepatite Metabolica Associata (MASH). In base all'accordo, Genflow mantiene tutti i diritti di proprietà intellettuale.
Heureka Labs, una spin-off tecnologica della Duke University, offre una piattaforma AI attualmente utilizzata dalle principali aziende farmaceutiche per accelerare la scoperta di farmaci attraverso la generazione di ipotesi e il riconoscimento di schemi nei dati biologici.
Genflow Biosciences (GENFF) ha entrado en una asociación estratégica con Heureka Labs, firmando un Master Services Agreement el 11 de abril de 2025. La colaboración proporciona a Genflow acceso a la plataforma de IA propietaria de Heureka, especializada en el análisis de datos genómicos y perfiles de expresión génica.
La asociación apoyará al candidato principal de Genflow, GF-1002, una terapia génica basada en SIRT6 que se encuentra en evaluación preclínica, y podría extenderse a otros programas, incluidos aquellos dirigidos a la Esteatohepatitis Asociada a Disfunción Metabólica (MASH). Según el acuerdo, Genflow retiene todos los derechos de propiedad intelectual.
Heureka Labs, una empresa derivada de la Universidad de Duke, ofrece una plataforma de IA que actualmente es utilizada por las principales compañías farmacéuticas para acelerar el descubrimiento de medicamentos mediante la generación de hipótesis y el reconocimiento de patrones en datos biológicos.
Genflow Biosciences (GENFF)는 Heureka Labs와 전략적 파트너십을 체결하고 2025년 4월 11일에 마스터 서비스 계약을 체결했습니다. 이 협력은 Genflow가 유전자 데이터와 유전자 발현 프로파일을 분석하는 데 특화된 Heureka의 독점 AI 플랫폼에 접근할 수 있도록 합니다.
이 파트너십은 Genflow의 주요 후보 GF-1002, SIRT6 기반 유전자 치료제가 현재 전임상 평가 중인 것을 지원하며, 대사 기능 장애와 관련된 지방간염(MASH)을 목표로 하는 다른 프로그램으로 확대될 수 있습니다. 계약에 따라 Genflow는 모든 지적 재산권을 보유합니다.
Heureka Labs는 듀크 대학교의 기술 스핀오프이며, 현재 주요 제약 회사들이 생물학적 데이터에서 가설 생성 및 패턴 인식을 통해 약물 발견을 가속화하는 데 사용하는 AI 플랫폼을 제공합니다.
Genflow Biosciences (GENFF) a conclu un partenariat stratégique avec Heureka Labs, signant un Master Services Agreement le 11 avril 2025. Cette collaboration permet à Genflow d'accéder à la plateforme IA propriétaire de Heureka, spécialisée dans l'analyse des données génomiques et des profils d'expression génique.
Le partenariat soutiendra le candidat principal de Genflow, GF-1002, une thérapie génique basée sur SIRT6 actuellement en évaluation préclinique, et pourrait s'étendre à d'autres programmes, y compris ceux ciblant la Stéatohépatite Associée à une Dysfonction Métabolique (MASH). Selon l'accord, Genflow conserve tous les droits de propriété intellectuelle.
Heureka Labs, un spin-off de l'Université Duke, propose une plateforme IA actuellement utilisée par les grandes entreprises pharmaceutiques pour accélérer la découverte de médicaments grâce à la génération d'hypothèses et à la reconnaissance de motifs dans les données biologiques.
Genflow Biosciences (GENFF) hat eine strategische Partnerschaft mit Heureka Labs eingegangen und am 11. April 2025 einen Master Services Agreement unterzeichnet. Die Zusammenarbeit ermöglicht es Genflow, auf die proprietäre KI-Plattform von Heureka zuzugreifen, die auf die Analyse von genomischen Daten und Genexpressionsprofilen spezialisiert ist.
Die Partnerschaft wird den Hauptkandidaten von Genflow, GF-1002, eine SIRT6-basierte Gentherapie in der präklinischen Evaluierung, unterstützen und könnte auf andere Programme ausgeweitet werden, einschließlich solcher, die auf die mit metabolischer Dysfunktion verbundene Steatohepatitis (MASH) abzielen. Im Rahmen des Vertrags behält Genflow alle IP-Rechte.
Heureka Labs, ein Spin-off der Duke University, bietet eine KI-Plattform an, die derzeit von führenden Pharmaunternehmen genutzt wird, um die Arzneimittelentdeckung durch Hypothesenbildung und Mustererkennung in biologischen Daten zu beschleunigen.
- Strategic access to advanced AI technology for drug discovery optimization
- Retention of all intellectual property rights
- Potential to accelerate development of multiple gene therapy programs
- Partnership with established platform used by leading pharmaceutical companies
- Lead candidate GF-1002 still in preclinical phase
- Financial terms of the agreement not disclosed
Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research
LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to announce that, in addition to the recently announced launch of a new development program in ophthalmology, it has entered into a strategic partnership with Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform.
A Master Services Agreement ("MSA") was signed by both parties on 11 April 2025, establishing a framework for long-term collaboration.
Under the terms of the MSA, Heureka Labs, a technology spin-off from Duke University, will provide Genflow with access to its proprietary artificial intelligence ("AI") platform, which specializes in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses. These insights will be key to optimising therapeutic design and anticipating patient-specific outcomes. Genflow will retain all IP rights under the MSA.
Initial efforts will support the Company's lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently in preclinical evaluation and may extend to future pipeline gene therapy programs, including those targeting Metabolic Dysfunction-Associated Steatohepatitis ("MASH").
Heureka's AI platform is designed to accelerate drug discovery processes by generating testable hypotheses, uncovering unexpected biological patterns, and improving the efficiency of research and development workflows. The platform is currently in use by leading pharmaceutical and biotechnology companies.
"Incorporating AI is no longer optional in bioinformatics research-it's essential for precision, speed, and scale," said Dr. Eric Leire, CEO of Genflow. "Heureka's AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on, accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Corporate Brokers |
|
Capital Plus Partners Ltd | |
Jon Critchley, +44 0203 821 6168 |
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
What is the purpose of GENFF's partnership with Heureka Labs?
When did GENFF sign the Master Services Agreement with Heureka Labs?
What therapeutic programs will benefit from GENFF's AI partnership?
Who owns the intellectual property rights in the GENFF-Heureka partnership?
